Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTR1siRNA is a small interfering RNA (siRNA) designed to silence the expression of the high affinity copper uptake protein 1 (CTR1), also known as SLC31A1. CTR1 is the primary transporter responsible for the influx of dietary copper into cells. In preclinical cardiovascular research, CTR1 has been identified as a mechanosensor in endothelial cells that responds to disturbed blood flow by promoting excessive copper uptake. This accumulation of copper leads to cuproptosis, a form of regulated cell death characterized by mitochondrial protein aggregation and respiratory dysfunction, which contributes to the development of atherosclerosis. By knocking down CTR1 expression, this siRNA prevents copper-mediated mitochondrial damage and has demonstrated the ability to reduce atherosclerotic lesions in animal models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CTR1siRNA.